Atmaram Pawar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Atmaram Pawar has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Priyanka Kandhare
Department of Pharmaceutical Quality Assurance, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, India
4 shared publications- Priyanka Kandhare
Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune 411038, India
2 shared publications Swati Korake
Department of Pharmaceutics, Bharati Vidyapeeth Deemed to Be University (BVDU), Poona College of Pharmacy, Pune 411038, India
2 shared publicationsA. Shaikh
Nanobioscience Group, Agharkar Research Institute, Pune 411004, India; Savitribai Phule Pune University, Pune 411004, India
1 shared publication- Abhishek Pawar
Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune-411038,India
1 shared publication Akshay Kamble
Department of Drug Regulatory Affairs, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune 411038, Maharashtra, India
1 shared publication
Latest Publications
- 18 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 83
From Detection to Prediction: AI-driven Process Analytical Technology for Nitrosamine and NDSRI Control in Pharmaceuticals
- 18 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 83
From Detection to Prediction: AI-driven Process Analytical Technology for Nitrosamine and NDSRI Control in Pharmaceuticals
- 23 April 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (5) , 314
Development and Evaluation of a Niosome-Integrated Microneedle System for Targeted Follicular Delivery of Ketoconazole in Alopecia Therapy
- 23 April 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (5) , 314
Development and Evaluation of a Niosome-Integrated Microneedle System for Targeted Follicular Delivery of Ketoconazole in Alopecia Therapy
- 16 January 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (2) , 102
Lipid-Polymer Hybrid Nanoparticles Loaded Hydrogel Formulation for Enhanced Topical Delivery of Itraconazole: in Vitro and in Vivo Studies
- 16 January 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (2) , 102
Lipid-Polymer Hybrid Nanoparticles Loaded Hydrogel Formulation for Enhanced Topical Delivery of Itraconazole: in Vitro and in Vivo Studies
- 28 September 2025
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 4 (4) , 1-13
Development and Characterization of Enzalutamide-Loaded Solid Lipid Nanoparticles for Enhanced Drug Delivery System
- 28 September 2025
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 4 (4) , 1-13
Development and Characterization of Enzalutamide-Loaded Solid Lipid Nanoparticles for Enhanced Drug Delivery System
- Open Access
- 13 June 2025
- Published by Elsevier in Medicine in Novel Technology and Devices
- Vol. 27
Artificial intelligence in pharmaceutical sciences: A comprehensive review
- 13 June 2025
- Published by Elsevier in Medicine in Novel Technology and Devices
- Vol. 27
Open AccessArtificial intelligence in pharmaceutical sciences: A comprehensive review
- 28 April 2025
- Published by Indian Drug Manufacturers' Association (IDMA) in INDIAN DRUGS
- Vol. 62 (04) , 61-64
PROBING THE REVERSAL OF NATURAL COLOR PREFERENCE IN ADULT ZEBRAFISH AFTER TRIMETHYLTIN INDUCED NEURODEGENERATION
For turmeric oil obtained from Curcuma longa L. and rosemary oil obtained from Rosmarinus officinalis L. there an limited reports for their effect against neurodegenerative disorders, besides the limited knowledge on formulation development and their evaluation for CNS disorders have tremendous future prospective. The objective of the study was evaluating the reversal of natural color preference and behavioral analysis associated with curcumin microemulsion (CUR ME) treatments in neurodegeneration induced adult zebrafish. The zebrafish were induced neurodegeneration using trimethyltin chloride followed by treatment. The color preference and behavioral analysis were recorded, analysed and interpreted. The results revealed the improved effect of CUR MEs over standard treatment. It was observed that the time spent in red zone was nearly regained after CUR ME treatment over standard treatment. Furthermore, the decreased path length was successfully improved after CUR ME treatment (p<0.05). Overall findings suggested the superior performance of CUR MEs over standard treatment and CUR solution treatment probing the potential of CUR MEs in the treatment of neurodegenerative disorders.
- 28 April 2025
- Published by Indian Drug Manufacturers' Association (IDMA) in INDIAN DRUGS
- Vol. 62 (04) , 61-64
PROBING THE REVERSAL OF NATURAL COLOR PREFERENCE IN ADULT ZEBRAFISH AFTER TRIMETHYLTIN INDUCED NEURODEGENERATION
For turmeric oil obtained from Curcuma longa L. and rosemary oil obtained from Rosmarinus officinalis L. there an limited reports for their effect against neurodegenerative disorders, besides the limited knowledge on formulation development and their evaluation for CNS disorders have tremendous future prospective. The objective of the study was evaluating the reversal of natural color preference and behavioral analysis associated with curcumin microemulsion (CUR ME) treatments in neurodegeneration induced adult zebrafish. The zebrafish were induced neurodegeneration using trimethyltin chloride followed by treatment. The color preference and behavioral analysis were recorded, analysed and interpreted. The results revealed the improved effect of CUR MEs over standard treatment. It was observed that the time spent in red zone was nearly regained after CUR ME treatment over standard treatment. Furthermore, the decreased path length was successfully improved after CUR ME treatment (p<0.05). Overall findings suggested the superior performance of CUR MEs over standard treatment and CUR solution treatment probing the potential of CUR MEs in the treatment of neurodegenerative disorders.
- Open Access
- 4 March 2025
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 4 (1) , 9
A Review on Revolutionizing Healthcare Technologies with AI and ML Applications in Pharmaceutical Sciences
Background/Objectives: The integration of Artificial Intelligence (AI) and Machine Learning (ML) in pharmaceutical research and development is transforming the industry by improving efficiency and effectiveness across drug discovery, development, and healthcare delivery. This review explores the diverse applications of AI and ML, emphasizing their role in predictive modeling, drug repurposing, lead optimization, and clinical trials. Additionally, the review highlights AI’s contributions to regulatory compliance, pharmacovigilance, and personalized medicine while addressing ethical and regulatory considerations. Methods: A comprehensive literature review was conducted to assess the impact of AI and ML in various pharmaceutical domains. Research articles, case studies, and industry reports were analyzed to examine AI-driven advancements in predictive modeling, computational chemistry, clinical trials, drug safety, and supply chain management. Results: AI and ML have demonstrated significant advancements in pharmaceutical research, including improved target identification, accelerated drug discovery through generative models, and enhanced structure-based drug design via molecular docking and QSAR modeling. In clinical trials, AI streamlines patient recruitment, predicts trial outcomes, and enables real-time monitoring. AI-driven predictive maintenance, process optimization, and inventory management have enhanced efficiency in pharmaceutical manufacturing and supply chains. Furthermore, AI has revolutionized personalized medicine by enabling precise treatment strategies through genomic data analysis, biomarker discovery, and AI-driven diagnostics. Conclusions: AI and ML are reshaping pharmaceutical research, offering innovative solutions across drug discovery, regulatory compliance, and patient care. The integration of AI enhances treatment outcomes and operational efficiencies while raising ethical and regulatory challenges that require transparent, accountable applications. Future advancements in AI will rely on collaborative efforts to ensure its responsible implementation, ultimately driving the continued transformation of the pharmaceutical sector.
- 4 March 2025
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 4 (1) , 9
Open AccessA Review on Revolutionizing Healthcare Technologies with AI and ML Applications in Pharmaceutical Sciences
Background/Objectives: The integration of Artificial Intelligence (AI) and Machine Learning (ML) in pharmaceutical research and development is transforming the industry by improving efficiency and effectiveness across drug discovery, development, and healthcare delivery. This review explores the diverse applications of AI and ML, emphasizing their role in predictive modeling, drug repurposing, lead optimization, and clinical trials. Additionally, the review highlights AI’s contributions to regulatory compliance, pharmacovigilance, and personalized medicine while addressing ethical and regulatory considerations. Methods: A comprehensive literature review was conducted to assess the impact of AI and ML in various pharmaceutical domains. Research articles, case studies, and industry reports were analyzed to examine AI-driven advancements in predictive modeling, computational chemistry, clinical trials, drug safety, and supply chain management. Results: AI and ML have demonstrated significant advancements in pharmaceutical research, including improved target identification, accelerated drug discovery through generative models, and enhanced structure-based drug design via molecular docking and QSAR modeling. In clinical trials, AI streamlines patient recruitment, predicts trial outcomes, and enables real-time monitoring. AI-driven predictive maintenance, process optimization, and inventory management have enhanced efficiency in pharmaceutical manufacturing and supply chains. Furthermore, AI has revolutionized personalized medicine by enabling precise treatment strategies through genomic data analysis, biomarker discovery, and AI-driven diagnostics. Conclusions: AI and ML are reshaping pharmaceutical research, offering innovative solutions across drug discovery, regulatory compliance, and patient care. The integration of AI enhances treatment outcomes and operational efficiencies while raising ethical and regulatory challenges that require transparent, accountable applications. Future advancements in AI will rely on collaborative efforts to ensure its responsible implementation, ultimately driving the continued transformation of the pharmaceutical sector.